JP2019182869A5 - - Google Patents

Download PDF

Info

Publication number
JP2019182869A5
JP2019182869A5 JP2019104161A JP2019104161A JP2019182869A5 JP 2019182869 A5 JP2019182869 A5 JP 2019182869A5 JP 2019104161 A JP2019104161 A JP 2019104161A JP 2019104161 A JP2019104161 A JP 2019104161A JP 2019182869 A5 JP2019182869 A5 JP 2019182869A5
Authority
JP
Japan
Prior art keywords
hydroxy
pyrrolidin
propan
dioxin
dihydrobenzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019104161A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019182869A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019182869A publication Critical patent/JP2019182869A/ja
Publication of JP2019182869A5 publication Critical patent/JP2019182869A5/ja
Pending legal-status Critical Current

Links

JP2019104161A 2013-09-20 2019-06-04 疾患治療用のグルコシルセラミドシンターゼ阻害剤 Pending JP2019182869A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361880752P 2013-09-20 2013-09-20
US61/880,752 2013-09-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016515409A Division JP6537500B2 (ja) 2013-09-20 2014-09-19 疾患治療用のグルコシルセラミドシンターゼ阻害剤

Publications (2)

Publication Number Publication Date
JP2019182869A JP2019182869A (ja) 2019-10-24
JP2019182869A5 true JP2019182869A5 (enExample) 2020-01-16

Family

ID=51794951

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016515409A Active JP6537500B2 (ja) 2013-09-20 2014-09-19 疾患治療用のグルコシルセラミドシンターゼ阻害剤
JP2019104161A Pending JP2019182869A (ja) 2013-09-20 2019-06-04 疾患治療用のグルコシルセラミドシンターゼ阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016515409A Active JP6537500B2 (ja) 2013-09-20 2014-09-19 疾患治療用のグルコシルセラミドシンターゼ阻害剤

Country Status (10)

Country Link
US (2) US10227323B2 (enExample)
EP (2) EP3912977A1 (enExample)
JP (2) JP6537500B2 (enExample)
CN (2) CN110372636B (enExample)
AU (2) AU2014321397C1 (enExample)
CA (1) CA2924545C (enExample)
IL (2) IL244628B (enExample)
MX (1) MX374452B (enExample)
TW (2) TWI690511B (enExample)
WO (1) WO2015042397A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX374452B (es) * 2013-09-20 2025-03-06 Biomarin Pharm Inc Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
US11744396B1 (en) * 2015-11-10 2023-09-05 Caffeine Innovations, LLC System, method, and device for agitating coffee grounds
CN105541819B (zh) * 2016-02-04 2018-09-14 浙江永宁药业股份有限公司 一种依匹唑派的制备方法及其中间体和中间体的制备方法
CN107216238A (zh) * 2016-03-21 2017-09-29 湖南师范大学 醇镁法制备4-甲基儿茶酚
JP6633814B2 (ja) * 2016-09-02 2020-01-22 アイジーエム グループ ビー.ヴィ. 光開始剤としての多環式グリオキシレート
WO2018118838A1 (en) * 2016-12-20 2018-06-28 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
US11014927B2 (en) 2017-03-20 2021-05-25 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
US11160280B2 (en) 2017-03-28 2021-11-02 Basf Se Pesticial compounds
UA127604C2 (uk) 2017-12-21 2023-11-01 Басф Се Пестицидні сполуки
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
CN111393405B (zh) * 2019-01-02 2022-11-25 中国科学院上海药物研究所 一类含氟取代的苯并噻吩类化合物及其药物组合物及应用
EP4005638A4 (en) * 2019-07-29 2023-07-05 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
EP4031132A4 (en) 2019-09-19 2023-09-13 Forma Therapeutics, Inc. Activating pyruvate kinase r
WO2021081141A1 (en) * 2019-10-23 2021-04-29 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
US12338237B2 (en) 2019-11-15 2025-06-24 Yuhan Corporation Derivatives having 1,2,3,4-tetrahydronaphthalene moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
CN118955495A (zh) * 2019-11-15 2024-11-15 柳韩洋行 具有2,3-二氢-1h-茚或2,3-二氢苯并呋喃部分的衍生物或其药学上可接受盐及含其的药物组合物
JP7725076B2 (ja) * 2020-04-28 2025-08-19 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン グルコシルセラミド合成酵素のピリジン阻害剤及びそれらを使用する治療方法
CN114621140B (zh) * 2020-12-10 2023-08-11 中国科学院上海药物研究所 芳基二氟乙酰胺化合物及其制备方法和用途
CN112457277B (zh) * 2020-12-16 2022-06-28 西安国康瑞金制药有限公司 一种他氟前列腺素的制备方法
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CN113912544B (zh) * 2021-11-29 2023-03-17 沧州普瑞东方科技有限公司 一种5-溴-1-甲基吲唑的制备方法
EP4573081A1 (en) * 2022-08-18 2025-06-25 Acelink Therapeutics, Inc. Crystalline forms of a glucosylceramide synthase inhibitor and uses thereof
CN115433157B (zh) * 2022-11-09 2023-02-07 苏州凯瑞医药科技有限公司 一种依利格鲁司特中间体的制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756528A (en) 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
PL205322B1 (pl) 1999-05-07 2010-04-30 Encysive Pharmaceuticals Inc Pochodne kwasu propionowego, środek farmaceutyczny i zastosowanie pochodnych kwasu propionowego
US6407064B2 (en) 1999-12-06 2002-06-18 Seikagaku Corporation Aminoalcohol derivative and medicament comprising the same
WO2002080920A1 (en) 2001-04-06 2002-10-17 Axys Pharmaceuticals, Inc. Arylacetamido-ketobenzoxazole as cysteine protease inhibitors
ES2399323T3 (es) 2001-07-16 2013-03-27 Genzyme Corporation Síntesis de inhibidores de la UDP-glucosa:N-acilesfingosina glucosiltransferasa
US6835831B2 (en) 2001-11-26 2004-12-28 Genzyme Corporation Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
AU2002367266A1 (en) 2001-12-28 2003-07-24 Sumitomo Pharmaceuticals Company, Limited Disease markers for renal diseaes and utilization thereof
AU2004220087A1 (en) 2003-03-06 2004-09-23 Seneb Biosciences, Inc. Methods and compositions for the enzymatic synthesis of gangliosides
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
AP2373A (en) * 2004-08-26 2012-03-07 Pfizer Enantiomerically pure aminoheteroaryl compounds asprotein kinase inhibitors.
WO2006053043A2 (en) 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
NZ556614A (en) 2005-01-26 2010-10-29 Allergan Inc 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroayryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity
HUE026057T2 (en) 2006-05-09 2016-05-30 Genzyme Corp Procedures for the Treatment of Fatty Liver Disease, which comprises inhibition of glycosphingolipid synthesis
WO2008011487A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
WO2008011483A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
US20100105687A1 (en) 2007-03-06 2010-04-29 Allergan, Inc. Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds
EP2167485B1 (en) * 2007-05-31 2015-09-30 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
EP2209473B1 (en) 2007-10-05 2017-11-22 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
MX2010004718A (es) 2007-11-01 2010-07-28 Acucela Inc Compuestos derivados de amina para tratar enfermedades y trastornos oftalmicos.
CN101998959B (zh) * 2008-02-06 2013-08-28 生物马林药物股份有限公司 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂
WO2009117150A2 (en) 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
US8389517B2 (en) 2008-07-28 2013-03-05 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
GB0817576D0 (en) 2008-09-25 2008-11-05 Lectus Therapeutics Ltd Calcium ion channel modulators & uses thereof
RU2578947C2 (ru) 2008-10-03 2016-03-27 Джензайм Корпорейшн Ингибиторы глюкозилцерамидсинтазы 2-ациламинопропанольного типа
MX381242B (es) * 2009-11-27 2025-03-12 Genzyme Corp Una forma amorfa y una cristalina de hemitartrato de genz 112638 como inhibidor de glucosilceramida sintasa.
US20110144081A1 (en) * 2009-12-15 2011-06-16 Henner Knust Pyrrolidine derivatives
US8961959B2 (en) * 2011-10-17 2015-02-24 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
EP2968268B1 (en) * 2013-03-15 2020-07-29 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
MX374452B (es) * 2013-09-20 2025-03-06 Biomarin Pharm Inc Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.

Similar Documents

Publication Publication Date Title
JP2019182869A5 (enExample)
JP2016534023A5 (enExample)
TWI567068B (zh) Trk抑制化合物
RU2586974C2 (ru) Ингибиторы катехол-о-метилтрансферазы и их применение при лечении психотических расстройств
JP4310109B2 (ja) ピラゾリル基を置換基として有する含窒素縮合環化合物およびその医薬組成物
US8492582B2 (en) N-acyl anthranilic acid derivative or salt thereof
JP2021169499A (ja) ヒト血漿カリクレイン阻害剤
US20210338653A1 (en) N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
BG108013A (bg) Заместени аминопроизводни и методи за използването им
KR20200136425A (ko) 옥사진 모노아실글리세롤 리파아제(magl) 억제제
JP2021533093A (ja) モノアシルグリセロールリパーゼ阻害剤としての新規複素環化合物
AU2006239418A1 (en) Novel oxadiazole derivatives and their medical use
EP3083611B1 (en) Oxindole derivatives, preparation thereof and therapeutic use in the treatment of ampk-related diseases
JP2020515575A5 (enExample)
KR20170094263A (ko) Nadph 옥시다제 억제제인 아미도 티아디아졸 유도체
JP2011530483A (ja) アミド化合物
EA022012B1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-a]ПИРАЗИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ, ПСИХИАТРИЧЕСКИХ И МЕТАБОЛИЧЕСКИХ РАССТРОЙСТВ И ЗАБОЛЕВАНИЙ
JP2009538358A (ja) 脂肪酸アミド加水分解酵素のオキサゾリルピペリジン・モジュレーター
JP7744350B2 (ja) 置換ピラゾロ-ピリミジンおよびその使用
CN115989228A (zh) 杂环化合物
KR20140041609A (ko) 선택적 프로테인 키나제 저해제로서 옥사졸 및 티아졸 유도체
JP2017523209A (ja) イミダゾピリダジン化合物
US20240299385A1 (en) 3-pyrrolylsulfonamide compounds as gpr17 antagonists
JP2022081710A (ja) 関節リウマチを治療するためのt型カルシウムチャネル阻害剤の使用
US20210179564A1 (en) Therapeutic compounds, compositions and methods of use thereof